Volume 14 Issue 1
Jan.  2023
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2023  >  14(1): 113-119
Zhang Minyue, Lan Ping, Gong Huilin, et al. Clinicopathological features analysis of focal segmental glomerulosclerosis after kidney transplantation[J]. ORGAN TRANSPLANTATION, 2023, 14(1): 113-119. doi: 10.3969/j.issn.1674-7445.2023.01.015
Citation: Zhang Minyue, Lan Ping, Gong Huilin, et al. Clinicopathological features analysis of focal segmental glomerulosclerosis after kidney transplantation[J]. ORGAN TRANSPLANTATION, 2023, 14(1): 113-119. doi: 10.3969/j.issn.1674-7445.2023.01.015
shu

Clinicopathological features analysis of focal segmental glomerulosclerosis after kidney transplantation

doi: 10.3969/j.issn.1674-7445.2023.01.015

  • Nephrology Hospital, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China

More Information
  • Corresponding author: Zheng Jin, Email: jzheng@mail.xjtu.edu.cn
  • Received Date: 2022-09-22
    Available Online: 2023-01-17
  • Publish Date: 2023-01-15
    Abstract
  •   Objective  To investigate the clinicopathological features of recurrent and de novo focal segmental glomerulosclerosis (FSGS) after kidney transplantation.  Methods  Thirty-four recipients pathologically diagnosed with FSGS by renal allograft biopsy were enrolled in this clinical trial. According to the detection of primary diseases of renal allografts and circulating permeability factors, 34 recipients were divided into the recurrent FSGS group (n=12) and de novo FSGS group (n=22). The differences of clinical indexes and the degree of pathological injury of renal allografts were compared between two groups.  Results  There was no significant difference in the mesangial hyperplasia score, glomerulosclerosis rate, renal tubular atrophy score, interstitial fibrosis score and podocyte proliferation rate between two groups (all P > 0.05). In the recurrent FSGS group, segmental glomerulosclerosis rate of the recipients was 0.10 (0.08, 0.27), lower than 0.19 (0.13, 0.33) in the de novo FSGS group (P < 0.05). No significant difference was found in the incidence of antibody-mediated rejection, drug-induced renal tubular injury and BK virus infection between two groups (all P > 0.05). The incidence of T cell-mediated rejection in the recurrent FSGS group was 17%, lower than 55% in the de novo FSGS group (P < 0.05). Immunohistochemical staining showed that the infiltrating inflammatory cells in the renal allografts were mainly T lymphocytes. The positive rates of C4d deposition in peripheral capillaries between the recurrent and de novo FSGS groups were 33% (4/12) and 32% (7/22), with no significant difference (P > 0.05). Immunofluorescence results revealed IgM deposition in the segmental glomerulosclerosis area of renal allografts in most cases. Electron microscopy showed extensive fusion or segmental distribution of podocytes in the glomerulus of renal allografts.  Conclusions  The degree of renal functional injury and the incidence of T cell-mediated rejection in the recurrent FSGS group are lower than those in the de novo FSGS group. Comprehensive analysis of preoperative and postoperative clinical manifestations, laboratory testing and pathological examination of kidney transplant recipients contribute to early diagnosis and treatment of recurrent and de novo FSGS.

     

    • FullText(HTML)
  • loading
    • References(35)
  • [1]
    黄远航, 范立明, 邓素雄, 等. 移植肾肾炎复发与新发患者的存活情况及影响因素分析[J]. 器官移植, 2019, 10(1): 67-73. DOI: 10.3969/j.issn.1674-7445.2019.01.010.

    HUANG YH, FAN LM, DENG SX, et al. Analysis of survival and influencing factors of patients with recurrent and de novo nephritis of renal allograft[J]. Organ Transplant, 2019, 10(1): 67-73. DOI: 10.3969/j.issn.1674-7445.2019.01.010.
    [2]
    JACOBS-CACHÁ C, VERGARA A, GARCÍA-CARRO C, et al. Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers[J]. Clin Kidney J, 2020, 14(2): 482-491. DOI: 10.1093/ckj/sfaa110.
    [3]
    O'SHAUGHNESSY MM, HOGAN SL, THOMPSON BD, et al. Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey[J]. Nephrol Dial Transplant, 2018, 33(4): 661-669. DOI: 10.1093/ndt/gfx189.
    [4]
    LIM WH, SHINGDE M, WONG G. Recurrent and de novo glomerulonephritis after kidney transplantation[J]. Front Immunol, 2019, 10: 1944. DOI: 10.3389/fimmu.2019.01944.
    [5]
    ZHU Y, FAN Y, XU F, et al. Focal segmental glomerulosclerosis superimposed on transplant glomerulopathy: implications for graft survival[J]. Am J Nephrol, 2021, 52(10/11): 788-797. DOI: 10.1159/000519648.
    [6]
    SHABAKA A, TATO RIBERA A, FERNÁNDEZ-JUÁREZ G. Focal segmental glomerulosclerosis: state-of-the-art and clinical perspective[J]. Nephron, 2020, 144(9): 413-427. DOI: 10.1159/000508099.
    [7]
    LOUPY A, HAAS M, SOLEZ K, et al. The Banff 2015 kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology[J]. Am J Transplant, 2017, 17(1): 28-41. DOI: 10.1111/ajt.14107.
    [8]
    GURUSWAMY SANGAMESWARAN KD, BARADHI KM. Focal segmental glomerulosclerosis[M]. Treasure Island (FL): StatPearls Publishing, 2022.
    [9]
    闵敏, 张炯. 利妥昔单抗治疗特发性局灶节段肾小球硬化的机制和疗效[J]. 肾脏病与透析肾移植杂志, 2021, 30(6): 575-580. DOI: 10.3969/j.issn.1006-298X.2021.06.016.

    MIN M, ZHANG J. Mechanism and efficacy of rituximab in idiopathic focal segmental glomerulosclerosis[J]. Chin J Nephrol Dial Transplant, 2021, 30(6): 575-580. DOI: 10.3969/j.issn.1006-298X.2021.06.016.
    [10]
    KIENZL-WAGNER K, WALDEGGER S, SCHNEEBERGER S. Disease recurrence-the sword of damocles in kidney transplantation for primary focal segmental glomerulosclerosis[J]. Front Immunol, 2019, 10: 1669. DOI: 10.3389/fimmu.2019.01669.
    [11]
    DE VRIESE AS, SETHI S, NATH KA, et al. Differentiating primary, genetic, and secondary FSGS in adults: a clinicopathologic approach[J]. J Am Soc Nephrol, 2018, 29(3): 759-774. DOI: 10.1681/ASN.2017090958.
    [12]
    RUDNICKI M. FSGS recurrence in adults after renal transplantation[J]. Biomed Res Int, 2016: 3295618. DOI: 10.1155/2016/3295618.
    [13]
    梅长林, 陈惠萍, 周新津. 临床肾脏病理学[M]. 北京: 人民卫生出版社, 2021.
    [14]
    UFFING A, PÉREZ-SÁEZ MJ, MAZZALI M, et al. Recurrence of FSGS after kidney transplantation in adults[J]. Clin J Am Soc Nephrol, 2020, 15(2): 247-256. DOI: 10.2215/CJN.08970719.
    [15]
    上海市医师协会肾脏内科医师分会局灶节段性肾小球硬化专家协作组. 成人局灶节段性肾小球硬化诊治专家共识[J]. 中华内科杂志, 2021, 60(9): 791-796. DOI: 10.3760/cma.j.cn112138-20210701-00454.

    Expert Collaboration Group of Focal Segmental Glomerulosclerosis of the Nephrologist Branch of Shanghai Medical Doctor Association. Expert consensus on diagnosis and treatment of focal segmental glomerulosclerosis in adults[J]. Chin J Intern Med, 2021, 60(9): 791-796. DOI: 10.3760/cma.j.cn112138-20210701-00454.
    [16]
    DE SOUZA L, PRUNSTER J, CHAN D, et al. Recurrent glomerulonephritis after kidney transplantation: a practical approach[J]. Curr Opin Organ Transplant, 2021, 26(4): 360-380. DOI: 10.1097/MOT.0000000000000887.
    [17]
    FRANCIS A, TRNKA P, MCTAGGART SJ. Long-term outcome of kidney transplantation in recipients with focal segmental glomerulosclerosis[J]. Clin J Am Soc Nephrol, 2016, 11(11): 2041-2046. DOI: 10.2215/CJN.03060316.
    [18]
    朱莹, 徐峰, 梁少姗, 等. 移植肾局灶节段性肾小球硬化的临床病理特征及预后[J]. 肾脏病与透析肾移植杂志, 2021, 30(2): 107-112. DOI: 10.3969/j.issn.1006-298X.2021.02.002.

    ZHU Y, XU F, LIANG SS, et al. Clinicopathological features and allograft outcomes of post-transplant focal segmental glomerulosclerosis[J]. Chin J Nephrol Dial Transplant, 2021, 30(2): 107-112. DOI: 10.3969/j.issn.1006-298X.2021.02.002.
    [19]
    THEOPHILUS UI, JOHN JR, IHAB S, et al. Recurrent focal segmental glomerulosclerosis after kidney transplantation in african americans: review of the current evidence[J]. Exp Clin Transplant, 2021, 19(12): 1245-1256. DOI: 10.6002/ect.2020.0542.
    [20]
    BUGLIONI A, FIDLER ME, ALEXANDER MP, et al. De novo pauci-immune glomerulonephritis in renal allografts[J]. Mod Pathol, 2020, 33(3): 440-447. DOI: 10.1038/s41379-019-0355-0.
    [21]
    HARSHMAN LA, BARTOSH S, ENGEN RM. Focal segmental glomerulosclerosis: risk for recurrence and interventions to optimize outcomes following recurrence[J]. Pediatr Transplant, 2022, 26(6): e14307. DOI: 10.1111/petr.14307.
    [22]
    朱莹. 移植肾复发和新发局灶节段性肾小球硬化的研究进展[J]. 医学研究生学报, 2021, 34(8): 861-865. DOI: 10.16571/j.cnki.1008-8199.2021.08.015.

    ZHU Y. Update on recurrent and de novo focal segmental glomerulosclerosis after kidney transplantation[J]. J Med Postgrad, 2021, 34(8): 861-865. DOI: 10.16571/j.cnki.1008-8199.2021.08.015.
    [23]
    BALOGLU I, TONBUL HZ, TURKMEN K, et al. Are kidney donor risk index/kidney donor profile index scores predictor of future graft function?[J]. Saudi J Kidney Dis Transpl, 2021, 32(4): 979-985. DOI: 10.4103/1319-2442.338310.
    [24]
    PARK SE, YOON SS, PARK SC, et al. Analysis of pre-transplant resuscitation factors influencing immediate graft function after deceased donor kidney transplantation[J]. Transplant Proc, 2018, 50(10): 3088-3094. DOI: 10.1016/j.transproceed.2018.08.011.
    [25]
    JAHN L, RÜSTER C, SCHLOSSER M, et al. Rate, factors, and outcome of delayed graft function after kidney transplantation of deceased donors[J]. Transplant Proc, 2021, 53(5): 1454-1461. DOI: 10.1016/j.transproceed.2021.01.006.
    [26]
    HUSAIN SA, KING KL, COLEY S, et al. Association between procurement biopsy findings and deceased donor kidney outcomes: a paired kidney analysis[J]. Transpl Int, 2021, 34(7): 1239-1250. DOI: 10.1111/tri.13899.
    [27]
    SHOJI J, MⅡ A, TERASAKI M, et al. Update on recurrent focal segmental glomerulosclerosis in kidney transplantation[J]. Nephron, 2020, 144(Suppl 1): 65-70. DOI: 10.1159/000510748.
    [28]
    PATEL RD, VANIKAR AV, NIGAM LA, et al. De novo focal segmental glomerulosclerosis in renal allograft-histological presentation and clinical correlation: single centre experience[J]. J Clin Diagn Res, 2017, 11(4): EC39-EC42. DOI: 10.7860/JCDR/2017/25502.9728.
    [29]
    HANSRIVIJIT P, GHAHRAMANI N. Combined rituximab and plasmapheresis or plasma exchange for focal segmental glomerulosclerosis in adult kidney transplant recipients: a meta-analysis[J]. Int Urol Nephrol, 2020, 52(7): 1377-1387. DOI: 10.1007/s11255-020-02462-6.
    [30]
    BOONPHENG B, HANSRIVIJIT P, THONGPRAYOON C, et al. Rituximab or plasmapheresis for prevention of recurrent focal segmental glomerulosclerosis after kidney transplantation: a systematic review and meta-analysis[J]. World J Transplant, 2021, 11(7): 303-319. DOI: 10.5500/wjt.v11.i7.303.
    [31]
    DIRIM AB, DEMIR E, GULLER N, et al. Efficacy of intravenous combined immunosuppression with plasmapheresis in adult patients with refractory primary focal segmental glomerulosclerosis[J]. J Clin Apher, 2022, 37(4): 376-387. DOI: 10.1002/jca.21985.
    [32]
    ALKANDARI O, NAMPOORY N, NAIR P, et al. Recurrent focal segmental glomerulosclerosis and abatacept: case report[J]. Exp Clin Transplant, 2016, 14(4): 456-459. DOI: 10.6002/ect.2014.0154.
    [33]
    ALHAMAD T, MANLLO DIECK J, YOUNUS U, et al. ACTH gel in resistant focal segmental glomerulosclerosis after kidney transplantation[J]. Transplantation, 2019, 103(1): 202-209. DOI: 10.1097/TP.0000000000002320.
    [34]
    ALLEN PJ, CHADBAN SJ, CRAIG JC, et al. Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes[J]. Kidney Int, 2017, 92(2): 461-469. DOI: 10.1016/j.kint.2017.03.015.
    [35]
    COSIO FG, FRANKEL WL, PELLETIER RP, et al. Focal segmental glomerulosclerosis in renal allografts with chronic nephropathy: implications for graft survival[J]. Am J Kidney Dis, 1999, 34(4): 731-738. DOI: 10.1016/S0272-6386(99)70400-2.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (314) PDF downloads(94) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return